Subscribe to RSS - home infusion

home infusion

Home infusion stakeholders await fallout


ALEXANDRIA, Va. – The list of home infusion contract suppliers in the Round 1 re-compete of competitive bidding includes some big names, but stakeholders say about half of the list includes companies without an associated pharmacy.

CVS buys Coram


LAKE FOREST, Calif. – CVS Caremark has agreed to acquire Apria’s home infusion business, Coram, for $2.1 billion, the companies announced today.

Pull home infusion from bid program, stakeholders say


ALEXANDRIA, Va. – Home infusion stakeholders say they are eyeing possible legislative fixes to address the inclusion of the therapy in competitive bidding.

Language lessons


DEERFIELD, Ill. – Working with patients on their own turf to adhere to treatment is always a challenge—even more so when there are language and cultural differences.

Apria building momentum, CEO says


LAKE FOREST, Calif. – Apria Healthcare has experienced its “strongest results” in several years, company officials said during an earnings call Aug. 9. 

BioScrip obtains credit facility


ELMSFORD, N.Y. – BioScrip has secured a $75 million revolving credit facility, it announced today in a press release. A portion of it will be used toward the purchase of Cincinnati-based CarePoint Partners.

Home infusion market stable, strong

Cost-effectiveness of therapy, steady reimbursement drive buyer interest, say analysts

When it comes to home infusion, big deals may be fewer and farther between, but there’s still a lot of runway for buyers and sellers looking to make smaller deals, say industry analysts. 

Mediware makes homecare play

'We have a lot of talent to help this group out'

LENEXA, Kan. – Mediware Information Systems has nearly doubled its customer base in the HME, home infusion and home health markets by acquiring Plainview, N.Y.-based Fastrack Healthcare Systems.

Apria positioned for 'added scale'


LAKE FOREST, Calif. – Execs at Apria Healthcare say the company is well-positioned going into Round 2 of competitive bidding.

Change your paying ways for home infusion drugs, OIG says


WASHINGTON – Taking the “blunt ax” of competitive bidding to home infusion drugs is the wrong way to reduce costs, say stakeholders, but in February, the Office of Inspector General (OIG) recommended CMS do just that.